Recommendations about add-on reimbursement for medical devices in France in September 2021

13

Oct 2021

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in September 2021. In total, 58 recommendations for registration, modification of registration conditions, and removal of devices in the List of reimbursable products and services (LPPR) were published. Opinions concern cardiovascular, orthopedic, peripheral vascular, and other groups of devices, as well as medical aids.

The first step in the assessment is the clinical (actual) benefit (SA), which can be either sufficient or insufficient. This step determines the insertion into the LPPR list. If sufficient, the clinical added value (ASA) is graded on a scale from I (major) to V (absent) for claimed indications, which supports the pricing decisions.

Examples of the opinions published in September are provided below. The full list of opinions can be found here.

  • Coronary endoprosthesis coated with everolimus XIENCE XPEDITION 48 by Abbott (application for registration; sufficient actual benefit; level V of clinical added value);
  • Single-chamber and dual-chamber implantable pacemakers ALIZEA SR 1300 and ALIZEA DR 1600 associated with the SMARTVIEW CONNECT remote monitoring system by MICROPORT CRM FRANCE (application for registration; sufficient actual benefit; level V of clinical added value);
  • AGENT paclitaxel-coated balloon catheter by Boston Scientific (application for registration; sufficient actual benefit in the treatment of in-stent clinical restenosis, and insufficient Actual Benefit in the treatment of de novo and small vessels; level V of clinical added value);
  • Self-expanding carotid stent CAROTID WALLSTENT MONORAIL by Boston Scientific (application for renewal of registration; sufficient actual benefit; level V of clinical added value);
  • Self-expanding venous stent ABRE by Medtronic (application for registration; sufficient actual benefit; level V of clinical added value);
  • Self-expanding venous stent VENOVO by BARD (application for registration; insufficient actual benefit);
  • Dual mobility acetabular cup DUALIS TRIPOD (cementless) by Gruppo Bioimpianti Srl (application for registration; sufficient actual benefit; level V of clinical added value);
  • Anatomically shaped bone implant for cranial, facial, and mandibular reconstructions POROUSITI by ORTHOPEDIE BIOMECA LOCOMOTION (application for registration; sufficient actual benefit; level V and level IV of clinical added value depending on the indications);
  • Dual mobility insert cup for total hip prosthesis RESTORATION ADM X3 by STRYKER (application for modification of registration conditions; sufficient actual benefit; level IV of clinical added value);
  • Food for special medical purposes for enteral nutrition SONDALIS HP 2KCAL by Nestle Health Science (application for registration; sufficient actual benefit; level V of clinical added value).

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

12

Oct 2021

On September 30, 2021, the 2020/21 National Tariff Payment System was published in England, and it came into effect on October 01, 2021. The publication has been delayed due to the COVID-19 pandemic.

Read more

08

Oct 2021

In September 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis, transapical transcatheter mitral valve-in-ring (TMVIR) after failed annuloplasty for mitral valve repair, and lateral elbow resurfacing for arthritis), and two new Medtech Innovation Briefings (Carnation Ambulatory Monitor, OrganOx metra for liver transplant). Also, one clinical guideline was updated.

Read more

07

Oct 2021

On September 10, 2021, it was announced that the Government of Spain had increased the budget allocated to the Spanish Network of Agencies for the Evaluation of Health Technologies and Benefits (RedETS) by 48.2% (compared to last year) for the development of the annual work plan. In total, the 2021 budget for the evaluation of health technologies in the National Health System amounts to €6,149,510. As a consequence of the budget increase, the RedETS 2021 Work Plan has included three new lines of evaluation.

Read more

01

Oct 2021

On August 26, 2021, the Dutch Healthcare Authority (NZa) published the fourth release of the DRG package for the year 2021 (RZ21d).

Read more

30

Sep 2021

At the beginning of September 2021, the Government of the Russian Federation released the preliminary version of the Program of State Guarantees for the period of 2022-2024. Major changes concerned the High-End Medical Care (HEMC) list I, where two new procedures in the cardiovascular and neurovascular field were added. The HEMC list II was expanded with the procedures in the field of radiotherapy, neurology, and neurosurgery, surgical procedures. The final version is expected at the beginning of 2022.

Read more